A.M.C. Sartori

Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunisation of infants in Brazil

Background Cost-effectiveness studies have been increasingly part of decision processes for incorporating new vaccines into the Brazilian National Immunisation Program. This study aimed to evaluate the cost-effectiveness of 10-valent pneumococcal conjugate vaccine (PCV10) in the universal childhood immunisation programme in Brazil. Methods A decision-tree analytical model based on the ProVac Initiative pneumococcus model was used, following 25 successive cohorts from birth until 5 years of age. Two strategies were compared: (1) status quo and (2) universal childhood immunisation programme with PCV10. Epidemiological and cost estimates for pneumococcal disease were based on National Health Information Systems and literature. A ‘top-down’ costing approach was employed. Costs are reported in 2004 Brazilian reals. Costs and benefits were discounted at 3%. Results 25 years after implementing the PCV10 immunisation programme, 10 226 deaths, 360 657 disability-adjusted life years (DALYs), 433 808 hospitalisations and 5 117 109 outpatient visits would be avoided. The cost of the immunisation programme would be R

Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil

10 674 478 765, and the expected savings on direct medical costs and family costs would be R

Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.

1 036 958 639 and R

Estimating health service utilization for treatment of pneumococcal disease: The case of Brazil

209 919 404, respectively. This resulted in an incremental cost-effectiveness ratio of R

PIN52 COST ESTIMATES IN THE ECONOMIC EVALUATIONS OF VACCINATION PROGRAMMES: THE CASES OF ROTAVIRUS AND VARICELLA IN BRAZIL

778 145/death avoided and R

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

22 066/DALY avoided from the society perspective. Conclusion The PCV10 universal infant immunisation programme is a cost-effective intervention (1–3 GDP per capita/DALY avoided). Owing to the uncertain burden of disease data, as well as unclear long-term vaccine effects, surveillance systems to monitor the long-term effects of this programme will be essential.

Revisão Sistemática Das Diretrizes De Análise De Impacto Orçamentário

This study conducts a cost-effectiveness analysis of a childhood universal varicella vaccination program in Brazil. An age and time-dependent dynamic model was developed to estimate the incidence of varicella for 30 years. Assuming a single-dose schedule; vaccine efficacy of 85% and coverage of 80%, the program could prevent 74,422,058 cases and 2905 deaths. It would cost R

A Sistematic Review Of The Cost-Effectiveness Of Vaccinating Elderly With The 23-Valent Pneumococcal Polysaccharide Vaccine (Ppv23)

3,178,396,110 and save R

Budget impact analysis of vaccines: what are the methodological issues?

660,076,410 to the society and R

Systematic Review Of Economic Evaluation Studies For Dengue Vaccine: How Valid Are The Results?

365,602,305 to the healthcare system. The program is cost-effective (R